Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated

Share this content:
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.
Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.

Cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma (RCC) may decrease cancer-specific mortality (CSM), a recent study suggests.

In a study of 851 patients with metastatic non-clear cell RCC, researchers found that patients who underwent cytoreductive nephrectomy had a significant 62% decreased risk of CSM than those who did not, according to results published online ahead of print in European Urology Focus.

The 2-year cumulative CSM rate was 52.6% for those who underwent cytoreductive nephrectomy group versus 77.7% for those who did not. The investigators observed a survival benefit of cytoreductive nephrectomy across histologic subtypes (papillary, chromophobe, collecting duct carcinoma).

Among contemporary patients (those diagnosed during 2010–2014), cytoreductive nephrectomy was associated with a 68% decreased risk of CSM.

Of the 851 patients, 67.6% underwent cytoreductive nephrectomy. The study population had a median age of 62 years and a median tumor size of 80 mm; 74.4% were men and 71.4% were white. Overall, 555 patients died during the study period.

Reference

Marchioni M, Bandini M, Preisser F, et al. Survival cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: A population-based study. Eur Urol Focus 2017; published online ahead of print.

You must be a registered member of Renal and Urology News to post a comment.